Marshall Wace, LLP Compass Therapeutics, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $115,806 - $202,107	36,881 Added 130.34%	65,177 $213,000
Q4 2022 Feb 14, 2023	SELL	$2.55 - $5.41 $59,975 - $127,243	-23,520 Reduced 45.39%	28,296 $142,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $53,369 - $94,659	28,089 Added 118.38%	51,816 $117,000
Q2 2022 Aug 15, 2022	BUY	$1.43 - $3.1 $33,929 - $73,553	23,727 New	23,727 $63,000

92M

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $161M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.